Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 9, 2002
Date of Patent:
June 24, 2008
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
Abstract: The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.
Type:
Grant
Filed:
October 9, 2003
Date of Patent:
June 17, 2008
Assignee:
Innogenetics N.V.
Inventors:
Eugeen Vanmechelen, Hugo Vanderstichele
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 2, 2002
Date of Patent:
May 27, 2008
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Colin K. Watanabe, William I. Wood
Abstract: The present invention provides a means for treatment and/or prevention of a disease caused by aberrant splicing, a neurodegenerative disease represented by Alzheimer's disease, or the like. The present invention relates to a nucleic acid which can be associated with generation of a splice variant that lacks exon 5 of presenilin-2 gene, an inhibitor for inhibiting a binding between protein-nucleic acid caused by aberrant splicing, and a method for screening the inhibitor.
Abstract: A novel gene apparently encoding a transmembrane glycoprotein has been successfully isolated by constructing a cDNA library of 4 kb or above in size from mRNA expressed in human adult brain and analyzing the structures of the cDNAs contained within said library by the shotgun method. The novel gene shows brain-specific expression and the protein encoded by said gene has a typical PDZ binding motif.
Type:
Grant
Filed:
December 7, 2004
Date of Patent:
March 18, 2008
Assignees:
Chugai Seiyaku Kabushiki Kaisha, Kazusa DNA Research Institute
Abstract: Disclosed are TGF-? polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
Type:
Grant
Filed:
January 15, 2002
Date of Patent:
February 12, 2008
Assignee:
Applied Protein Sciences, LLC
Inventors:
Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
Abstract: The present invention relates to a novel lacrimal gland protein (designated lacritin) and the nucleic acid sequences encoding that protein. Lacritin has activity as a growth factor on both human corneal epithelial cells and on the lacrimal acinar cells that produce it. Accordingly, one embodiment of the present invention is directed to the use of lacritin to treat Dry Eye and other disorders requiring the wetting of the eye.
Type:
Grant
Filed:
March 6, 2007
Date of Patent:
January 22, 2008
Assignee:
University of Virginia Patent Foundation
Inventors:
Gordon W. Laurie, Sandhya Sanghi, Kumar Rajesh, Angela J. Lumsden
Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Also included is the mature GGF peptide and the DNA encoding said peptide, exclusive of the N-terminal signal sequence. The mature GGF peptide and DNA encoding the same are also useful for treatment of conditions of the central nervous system. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
Type:
Grant
Filed:
October 22, 1996
Date of Patent:
January 15, 2008
Assignees:
Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
Inventors:
Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
Abstract: A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.
Type:
Grant
Filed:
July 11, 2003
Date of Patent:
December 25, 2007
Assignee:
University of Washington
Inventors:
Ryo Kubota, Thomas A Reh, Andrew J Fischer
Abstract: The invention relates to neuroprotection and to medicaments for use therein. Neuroprotection is induced by activation of neural growth hormone receptors, primarily using medicaments comprising growth hormone, growth hormone analogs or ligands which are functionally equivalent. Such medicaments may also include one or more secondary neuroprotective agents.
Type:
Grant
Filed:
September 3, 1999
Date of Patent:
December 4, 2007
Assignee:
Neuren Pharmaceuticals Ltd.
Inventors:
Arjan Scheepens, Christopher E. Williams, Peter David Gluckman, Ross Graham Clark
Abstract: The invention involves prophylaxis or treatment of nervous system pathological conditions. This is accomplished by administering secretable glial growth factors, such as the molecule referred to as GGF-2.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
October 23, 2007
Assignees:
Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
Inventors:
Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
Abstract: The present invention relates to human PGF polypeptides and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques, and antibodies and antagonist/inhibitors against such polypeptides. Also provided are methods of using such polypeptides therapeutically for treating prostate cancer, to promote tissue regeneration and to facilitate wound healing. Also provided is a diagnostic assay to detect prostate cancer and benign prostatic hyperplasia.
Type:
Grant
Filed:
October 15, 2002
Date of Patent:
October 16, 2007
Assignee:
Human Genome Sciences, Inc.
Inventors:
Peter L. Hudson, Craig A. Rosen, Wei-Wu He
Abstract: The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also provides methods of inhibiting the Mob-5 receptor as well as methods of detecting cancer by detecting the presence of the Mob-5 receptor.
Abstract: The present invention relates to three novel genes and polypeptides derived therefrom encoding ā?2?-Cā and/or ā?2?-Dā proteins which exist as a subunit in many calcium channels. The invention also describes methods for using the novel gene and polypeptides in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, binding assays in connection with chemical databases, gene therapy.
Type:
Grant
Filed:
October 7, 1999
Date of Patent:
August 28, 2007
Assignee:
Warner Lambert Company
Inventors:
Margaret Ann Johns, Brian Moldover, James David Offord
Abstract: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
May 8, 2002
Date of Patent:
May 22, 2007
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.
Type:
Grant
Filed:
April 28, 2004
Date of Patent:
April 3, 2007
Assignee:
Lexicon Genetics Incorporated
Inventors:
D. Wade Walke, Xiaoming Wang, John Scoville, C. Alexander Turner, Jr.
Abstract: Disclosed is the characterization and purification of DNA encoding polypeptides useful for the stimulation of glial cell mitogenesis. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides in the prevention or treatment of multiple sclerosis.
Type:
Grant
Filed:
October 22, 1996
Date of Patent:
March 20, 2007
Assignees:
Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
Inventors:
Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
September 16, 2002
Date of Patent:
March 20, 2007
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Colin K. Watanabe, William I. Wood, Zemin Zhang
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
September 16, 2002
Date of Patent:
March 13, 2007
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, J. Christopher Grimaldi, Austin L. Gurney, Colin K. Watanabe, William I. Wood, Zemin Zhang